




Searching News Database: imatinib
HSMN NewsFeed - 30 Nov 2017
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
HSMN NewsFeed - 11 Nov 2016
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
HSMN NewsFeed - 2 Jun 2016
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
HSMN NewsFeed - 2 Jul 2013
ARIAD Announces Marketing Authorization for Iclusig(R) (ponatinib) in the European Union
ARIAD Announces Marketing Authorization for Iclusig(R) (ponatinib) in the European Union
HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
HSMN NewsFeed - 20 Jan 2010
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
HSMN NewsFeed - 21 Apr 2008
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT
HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
HSMN NewsFeed - 31 May 2007
Panacea Pharmaceuticals Announces the Availability of PC Detect(sm) for Prostate Cancer Screening
Panacea Pharmaceuticals Announces the Availability of PC Detect(sm) for Prostate Cancer Screening
HSMN NewsFeed - 8 Feb 2007
Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
HSMN NewsFeed - 10 Jan 2007
Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
HSMN NewsFeed - 14 Nov 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
HSMN NewsFeed - 28 Apr 2006
Pfizer's Sutent Receives Positive Opinion in the European Union For Two Difficult-To-Treat Advanced Cancers
Pfizer's Sutent Receives Positive Opinion in the European Union For Two Difficult-To-Treat Advanced Cancers
HSMN NewsFeed - 10 Apr 2006
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer
HSMN NewsFeed - 5 Jan 2006
Innovive Pharmaceuticals Licenses Potent Dual Bcr-Abl/Lyn Kinase Inhibitor
Innovive Pharmaceuticals Licenses Potent Dual Bcr-Abl/Lyn Kinase Inhibitor
Additional items found! 26

Members Archive contains
26 additional stories matching:
imatinib
(Password required)
imatinib
(Password required)